Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Alabama at Birmingham
About this trial
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.
We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
Eligibility criteria
Qualifiers
Healthy adult
Disqualifiers
No prior history of pneumococcal vaccination
No immunosuppressing medications or chronic diseases that affect immune function
Trial design
Treatments tested in this trial
- Pneumococcal Vaccine
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov